Vertex Pharmaceuticals Inc. (VRTX) said that Health Canada has granted Marketing Authorization for CASGEVY (exagamglogene ...

He is also working to reduce toxicities and maximize the cancer-killing powers of transplanted immune cells. One of Dr. Storb’s major scientific contributions is the non-myeloablative transplant.

Reduced-intensity conditioning regimes for HSCT candidates have similar short-term outcomes as HSCT candidates receiving myeloablative conditioning. Partial HLA-matched cord blood is a viable stem ...

Behçet's disease (BD) is a systemic large-vessel vasculitis characterized by a wide clinical spectrum including recurrent oral and genital ulcerations, uveitis, and vascular, neurological ...

Standard ALL treatment usually takes between 2 to 3 years. The maintenance phase takes up most of this time as it lasts 2 years. During the maintenance phase people often go back to work or college.

The transformative capacity of cells as therapeutics has revolutionised malignancy treatments.1 Cellular engineering advances ...

A few days before Casgevy is infused, patients undergo myeloablative chemo to wipe out their bone marrow, removing unhealthy blood stem cells and making room for the new, edited versions.

To reduce duration of neutropenia and related sequelae in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone-marrow transplantation (BMT). To mobilize ...

Dinutuximab beta is used in children who previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation ...

Zevalin-mini allo; The major goal of this project is to conduct a Phase II trial evaluating the efficacy of Non-myeloablative 90Y-anti-CD20 Antibody, Fludarabine, Low-Dose total body irradiation (TBI) ...